
Viking Therapeutics, Inc.
NASDAQ•VKTX
CEO: Dr. Brian Lian Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-04-28
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Contact Information
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, 92121, United States
858-704-4660
Market Cap
$3.83B
P/E (TTM)
-16.0
38.2
Dividend Yield
--
52W High
$43.15
52W Low
$18.92
52W Range
Rank63Top 94.0%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.81+268.18%
4-Quarter Trend
FCF
-$94.00M+328.03%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
R&D Spending Surge Nine-month R&D expenses hit $191.5M, marking a substantial 171.0% increase compared to $70.7M in 2024.
VK2735 Phase 3 Launch Initiated VANQUISH Phase 3 program for VK2735 subcutaneous dosing in June 2025 for obesity treatment.
Strong Cash Position Total cash and investments reached $714.6M as of September 30, 2025, funding operations through 2026.
Oral VK2735 Success Announced positive top-line results for oral VK2735 Phase 2 trial in August 2025, showing significant weight reduction.
Risk Factors
Accelerated Operating Losses Nine-month net loss widened to $(202.0M) in 2025 versus $(74.5M) in the prior comparable period.
High R&D Cost Burn Operating cash used increased to $(193.4M) for nine months due to advancing clinical studies costs.
Future Capital Requirements Expect continued material losses, necessitating raising additional equity or debt capital on uncertain terms.
Clinical Development Uncertainty Success of drug candidates is not guaranteed; regulatory approval may be delayed or denied across pipeline.
Outlook
Advance VK2735 Pipeline Continue advancing VK2735 subcutaneous Phase 3 and oral Phase 2 programs through clinical milestones.
Seek DACRA IND Filing Plan to file Investigational New Drug application for the DACRA obesity program in the fourth quarter of 2025.
Seek VK0214 Partnerships Intent to pursue partnering or licensing opportunities for the VK0214 X-ALD program following Phase 1b data.
Manage Lease Transition Executed amendment for new corporate headquarters lease, effective upon substitution date in early 2026.
Peer Comparison
Revenue (TTM)
ADMA$488.56M
MIRM$471.79M
LGND$251.23M
Gross Margin (Latest Quarter)
NAMS100.0%
CRNX100.0%
SLNO98.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CRNX | $5.74B | -12.5 | -35.1% | 4.1% |
| KYMR | $5.49B | -20.6 | -33.4% | 7.6% |
| MIRM | $4.71B | -127.7 | -16.5% | 40.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 4, 2026
EPS:-$0.89
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 23, 2025|Revenue: $0.00+0.0%|EPS: $-0.81+268.2%N/AForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 23, 2025|Revenue: $0.00+0.0%|EPS: $-0.58+190.0%N/AForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 24, 2025|Revenue: $0.00+0.0%|EPS: $-0.41+57.7%N/AForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 26, 2025|Revenue: $0.00+0.0%|EPS: $-1.01-11.0%N/AForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 23, 2024|Revenue: $0.00+0.0%|EPS: $-0.22-4.3%N/AForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 24, 2024|Revenue: $0.00+0.0%|EPS: $-0.20+5.3%N/AForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 25, 2024|Revenue: $0.00+0.0%|EPS: $-0.26+8.3%N/AForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 7, 2024|Revenue: $0.00+0.0%|EPS: $-0.91-3.4%N/A